Stephen K. Tyring MD, PhDClinical Professor, Departments of Dermatology, Microbiology/Molecular Genetics and Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas
Dr Stephen Tyring is a Clinical Professor in the Departments of Dermatology, Microbiology/Molecular Genetics and Internal Medicine at the University of Texas Health Science Center at Houston. Dr. Tyring is former President of the Texas Dermatological Society (2009-2010). He is board certified by the American Academy of Dermatology (AAD), and is a member of the Infectious Disease Society of America, as well as the American Federation for Clinical Research.
Dr Tyring is an Assistant Editor for the J Am Acad Dermatol, and sits on several editorial boards as well as serves as a reviewer for a number of journals including the N Eng J Med, Lancet, JAMA/JAMA Dermatol, J Infect Dis & Ann Intern Med. A principal investigator for over 200 successfully completed clinical trials, Dr. Tyring’s research interests include the therapy and prevention of various mucocutaneous diseases, especially those disorders with an infectious and/or immunological basis. Dr. Tyring is the author of over 700 journal articles and book chapters as well as ten books.
Recent Contributions to PracticeUpdate:
- Topical Cidofovir for the Treatment of Recalcitrant Viral Warts and Molluscum Contagiosum in Jacobsen Syndrome
- Vaccination Against HPV
- Intralesional Cidofovir for Treatment of Recalcitrant Warts in Both Immunocompetent and Immunocompromised Patients
- Association Between Fetal Safety Outcomes and Exposure to Local Podophyllotoxin During Pregnancy
- Recalcitrant Cutaneous Warts Treated With Quadrivalent HPV Vaccine
- Intralesional vs Intramuscular Bivalent HPV Vaccine in the Treatment of Recalcitrant Common Warts
- Occurrence of Extensive Cutaneous HPV Infection After Initiation of Tofacitinib Therapy
- Pearls From the Fall Clinical Dermatology Meeting 2018: Update on Vaccines in Dermatology
- EADV 2018: HPV Vaccination Rates Are Too Low to Permanently End the Chain of Infection
- The 9-Valent HPV Vaccine for Treatment of Squamous Cell Carcinomas